ARROWHEAD PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.53 USD | -4.82% |
|
-11.26% | -26.37% |
Financials (USD)
| Sales 2024 * | 126M | Sales 2025 * | 181M | Capitalization | 2.79B |
|---|---|---|---|---|---|
| Net income 2024 * | -313M | Net income 2025 * | -300M | EV / Sales 2024 * | 18.8 x |
| Net cash position 2024 * | 426M | Net cash position 2025 * | 313M | EV / Sales 2025 * | 13.7 x |
| P/E ratio 2024 * |
-8.62
x | P/E ratio 2025 * |
-9.32
x | Employees | 525 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Arrowhead Pharmaceuticals, Inc.
More recommendations
More press releases
| 1 day | -4.82% | ||
| 1 week | -12.27% | ||
| Current month | -21.22% | ||
| 1 month | -19.94% | ||
| 3 months | -32.06% | ||
| 6 months | -13.31% | ||
| Current year | -26.37% |
1 week
22.47
25.50
1 month
22.4729.93
Current year
22.4739.83
1 year
20.6742.48
3 years
20.6793.66
5 years
17.3093.66
10 years
1.2093.66
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 07-11-30 | |
| Director of Finance/CFO | 57 | 08-12-31 | |
Peter Carignan
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Douglass Given
CHM | Chairman | 71 | 10-11-22 |
Michael Perry
BRD | Director/Board Member | 64 | 11-12-18 |
Adeoye Olukotun
BRD | Director/Board Member | 79 | 20-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.40% | 0 M€ | 0.00% | - | |
| 0.35% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 22.53 | -4.82% | 1,149,578 |
| 24-04-16 | 23.67 | -1.42% | 796,315 |
| 24-04-15 | 24.01 | -2.79% | 878,553 |
| 24-04-12 | 24.7 | -3.82% | 856,153 |
| 24-04-11 | 25.68 | +1.14% | 708,522 |
Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT
More quotes
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.
Calendar
2024-05-06
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
23.67
USD
Average target price
55.15
USD
Spread / Average Target
+133.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.37% | 2.93B | |
| -3.39% | 102B | |
| +2.61% | 96.09B | |
| -1.02% | 22.05B | |
| -18.14% | 20.81B | |
| -6.87% | 19.06B | |
| -40.70% | 16.05B | |
| -26.89% | 14.01B | |
| +1.12% | 13.38B | |
| +22.25% | 11.01B |
- Stock Market
- Equities
- ARWR Stock
